Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud

Hims & Hers Health Inc. surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform.

Novo and Hims plan to announce a new partnership as soon as Monday, according to a person familiar with the matter, who spoke on the condition of anonymity. The two companies had a similar agreement last year, but Novo abruptly scrapped it after Hims refused to stop marketing and selling copycat medications.

Hims shares soared 47% in trading before US exchanges opened. Novo climbed less than ...